|Drug class||antiplatelet drug|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||532.450 g·mol−1|
|3D model (JSmol)|
Regrelor (also known as INS50589) is an experimental antiplatelet drug that was under investigation by Merck Sharp and Dohme in human clinical trials. Although it was initially found to be well tolerated in healthy subjects, safety concerns led to cessation of clinical trials.
Regrelor is an experimental drug. It is classified as an antiplatelet medication. It was under investigation for use in blood clotting problems, as well as during coronary artery bypass surgery.
Regrelor is available in an intravenous formulation.
Regrelor is classified as a purinergic P2 receptor (P2Y12) antagonist. Other compounds in the same mechanistic class include clopidogrel and ticagrelor. It is characterized as a reversible, competitive receptor antagonist. The IC50 for antagonism of ADP-induced (P2Y12-mediated) platelet aggregation was 16 nM in vitro.
Regrelor's primary metabolite is called INS51088.
Regrelor is structurally similar to AMP, just like ticagrelor. Regrelor has 4 hydrogen bond donors and 11 acceptors. It is produced as a disodium salt. The two sodium atoms bind the negatively charged phosphate moiety in solution.
Regrelor was synthesized from adenosine diphosphate (ADP), an endogenous chemical involved in metabolism. The authors noted that the addition of a lipophilic moiety like cinnamaldehyde at the C-2' and C-3' positions, combined with ethylurea at N-6 on the adenine base, yielded regrelor.
Regrelor was developed around the same time as prasugrel and cangrelor. After Inspire Pharmaceuticals initially developed the drug, it was purchased by Merck Sharp and Dohme.
Pre-clinical experiments in rats, dogs, and monkeys found that the drug acted quickly to inhibit platelet aggregation, and that baseline function was restored quickly after discontinuation of treatment.
In a phase 1 clinical trial sponsored by Merck Sharp and Dohme Corporation, regrelor was well tolerated in healthy volunteers. In 2008, phase 2 trials were discontinued. It is believed that further development of the drug was ceased due to safety reasons. In the trial, there was an increased risk of bleeding for patients on regrelor.
- ^ a b c Moliterno DJ (December 2008). "Advances in antiplatelet therapy for ACS and PCI". Journal of Interventional Cardiology. 21 Suppl 1 (Suppl 1): S18-24. doi:10.1111/j.1540-8183.2008.00409.x. PMID 19090933.
- ^ a b "Regrelor". Adis Insight. Springer International Publishing AG. Retrieved 3 August 2017.
- ^ a b c d e Chackalamannil S, Rotella D, Ward S (3 June 2017). Comprehensive Medicinal Chemistry (III ed.). Elsevier. p. 568. ISBN 978-0-12-803201-5.
- ^ a b "Regrelor". PubChem. National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Retrieved 3 August 2017.
- ^ a b c d Johnson FL, Boyer JL, Leese PT, Crean C, Krishnamoorthy R, Durham T, et al. (August 2007). "Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589". Platelets. 18 (5): 346–56. doi:10.1080/09537100701268741. PMID 17654304. S2CID 31681877.
- ^ a b c "Regrelor Disodium". Pharmacodia. Pharmacodia Holding Ltd. Retrieved 3 August 2017.
- ^ Nave CR (2005). "Adenosine Triphosphate". Hyper Physics [serial on the Internet]. Georgia State University.
- ^ Douglass JG, Patel RI, Yerxa BR, Shaver SR, Watson PS, Bednarski K, et al. (February 2008). "Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor". Journal of Medicinal Chemistry. 51 (4): 1007–25. doi:10.1021/jm701348d. PMID 18232657.
- ^ Clinical trial number NCT00099450 for "Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers" at ClinicalTrials.gov